Japan Drug Approvals — March 2026
Japan Drug
Approvals — March 2026
Japan’s PMDA approved 3 drugs in March 2026, spanning CNS diagnostics, oncology, and infectious disease: Gadoquatrane (MRI contrast agent), Risovalisib (PI3Kα inhibitor for ovarian clear cell carcinoma), and Doravirine/Islatravir (RT inhibitor combination for HIV).
3 drugs approved in Japan — March 2026
All data from the March 2026 monthly report, Table 0. All 3 approvals are small molecule drugs.
| Drug | Target | Modality | Indication | Developer | Date |
|---|---|---|---|---|---|
| Gadoquatrane | — | Contrast agent; Small molecule drug | Central Nervous System Diseases; Contrast agents | Bayer Yakuhin Ltd. | Mar 23 |
| Risovalisib | PI3Kα | Small molecule drug | Ovarian clear cell carcinoma | Haihe Biopharma Co., Ltd. | Mar 23 |
| Doravirine / Islatravir | RT | Small molecule drug | HIV Infections | MSD KK (Tokyo) | Mar 6 |
All three Japan March 2026 approvals profiled
Gadoquatrane — MRI contrast agent for CNS imaging
Gadoquatrane is a contrast agent and small molecule drug developed by Bayer Yakuhin Ltd., approved by Japan’s PMDA on March 23, 2026 for Central Nervous System Diseases and contrast agent use. Gadoquatrane is a macrocyclic gadolinium-based contrast agent (GBCA) designed for MRI applications, with the macrocyclic structure providing high thermodynamic and kinetic stability and reducing free gadolinium release compared to linear GBCAs.
Contrast agent · CNS · MRI · BayerRisovalisib — PI3Kα inhibitor for ovarian clear cell carcinoma
Risovalisib is a small molecule drug targeting PI3Kα, developed by Haihe Biopharma Co., Ltd., approved by Japan’s PMDA on March 23, 2026 for ovarian clear cell carcinoma. Ovarian clear cell carcinoma (OCCC) is a distinct histological subtype of ovarian cancer characterised by a high frequency of PIK3CA mutations (encoding PI3Kα), making PI3Kα inhibition a mechanistically targeted approach for this subtype where platinum-based chemotherapy shows limited efficacy.
PI3Kα · Small molecule · Ovarian CCC · Haihe BiopharmaDoravirine / Islatravir — RT inhibitor combination for HIV
Doravirine/Islatravir is a small molecule drug combination targeting reverse transcriptase (RT), developed by MSD KK (Tokyo), approved by Japan’s PMDA on March 6, 2026 for HIV Infections. Doravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and Islatravir is a nucleoside reverse transcriptase translocation inhibitor (NRTTI) — combining two mechanistically distinct inhibitors of HIV reverse transcriptase in a once-daily regimen. This two-drug regimen represents a streamlined alternative to three-drug antiretroviral combinations.
RT · NNRTI + NRTTI · HIV · MSD3 signals from Japan’s March 2026 approval data
Strategic takeaways derived from the 3 PMDA approvals in the March 2026 monthly report.
Risovalisib: PI3Kα targeting for a PIK3CA-driven ovarian subtype
Risovalisib’s approval in Japan for ovarian clear cell carcinoma positions PI3Kα inhibition as a targeted approach for a subtype with high PIK3CA mutation frequency. OCCC is largely resistant to platinum-based chemotherapy and represents a high-unmet-need histological subtype. The development by Haihe Biopharma — a Chinese company achieving PMDA approval — also reflects the maturing cross-border regulatory ambitions of China’s biopharma sector.
Doravirine/Islatravir: two-drug HIV regimen approved in Japan
The Doravirine/Islatravir combination’s PMDA approval on March 6, 2026 adds a two-drug antiretroviral option to Japan’s HIV treatment landscape. The combination of an NNRTI (Doravirine) with an NRTTI (Islatravir) — a newer mechanistic class — provides dual RT inhibition with a reduced pill burden relative to three-drug standard-of-care regimens. Islatravir’s NRTTI mechanism represents a distinct HIV reverse transcriptase inhibition approach compared to established nucleoside analogue classes.
Gadoquatrane: macrocyclic GBCA strengthens high-stability contrast agent portfolio
Gadoquatrane’s PMDA approval adds a macrocyclic gadolinium-based contrast agent option to Japan’s CNS MRI diagnostic toolkit. Regulatory focus on GBCA safety — particularly gadolinium deposition in the brain associated with linear GBCAs — has driven global preference shifts toward macrocyclic agents. Gadoquatrane’s macrocyclic structure provides higher thermodynamic and kinetic stability, aligning with this safety-driven market trend across Japan and other major MRI markets.
Haihe Biopharma secures PMDA approval: China-origin drug in Japan oncology
Risovalisib’s approval in Japan from Haihe Biopharma Co., Ltd. — a China-based developer — is notable as a marker of Chinese oncology programs achieving regulatory approval in Japan’s historically selective PMDA review environment. Alongside the ADC Orphan Drug designation for Risvutatug Rezetecan (GSK, Japan, March 2026), this signals Japan’s growing receptivity to innovative oncology agents from Asian developers beyond domestic players.
Japan drug approvals March 2026 — key questions
Japan’s PMDA approved 3 drugs in March 2026: Gadoquatrane (a contrast agent and small molecule drug for Central Nervous System Diseases), Risovalisib (a PI3Kα inhibitor small molecule drug for ovarian clear cell carcinoma), and Doravirine/Islatravir (a reverse transcriptase inhibitor small molecule drug for HIV infections).
Risovalisib, a small molecule drug targeting PI3Kα, developed by Haihe Biopharma Co., Ltd., was approved by Japan’s PMDA on March 23, 2026 for ovarian clear cell carcinoma.
Gadoquatrane, a contrast agent and small molecule drug developed by Bayer Yakuhin Ltd., was approved by Japan’s PMDA on March 23, 2026 for Central Nervous System Diseases and contrast agent use.
Doravirine/Islatravir, a reverse transcriptase (RT) inhibitor small molecule drug developed by MSD KK (Tokyo), was approved by Japan’s PMDA on March 6, 2026 for HIV Infections.
Risovalisib was developed by Haihe Biopharma Co., Ltd. and received PMDA approval in Japan on March 23, 2026 for ovarian clear cell carcinoma.
Data on this page is sourced from the PatSnap March 2026 monthly pharmaceutical report, Table 0 (drug approvals). Represents a snapshot of available records as of March 2026.